Table 10.
Commercially available clinical genosensors and their characteristics.
|
Company |
Model | Sensitivity | Specificity | Sample | Virus | Reference |
|---|---|---|---|---|---|---|
| Quidel, USA |
Solana Influenza A + B Assay | Influenza A: 97.2% (95% CI 95.0%–98.4%) Influenza B: 100.0% (95% CI 95.4%–100%) |
Influenza A: 96.7% (95% CI 95.4%–97.7%) Influenza B: 98.9% (95% CI 98.2%–99.4%) |
nasal and nasopharyngeal swabs | Influenza A&B | [292] |
| Lyra Influenza A + B Assay | A: 100% B: 98.4% |
A: 98.7% B: 95.5% |
nasal swabs | Influenza A (HIN1,H3N2,H7N9) &B | ||
| Solana SARS-CoV-2 Assay | Nasal: 97.2% Nasopharyngeal: 100% |
Nasal: 100% Nasopharyngeal: 96.9% |
Nasal swabs and nasopharyngeal swabs | SARS-CoV-2 | ||
| Lyra RSV + hMPV Assay | RSV 96% hMPV 95% | RSV 98% hMPV 98.9% | Nasal swabs And nasopharyngeal swab |
Respiratory syncytial virus (RSV) and Human metapneumovirus (hMPV) | ||
| Alere, USA |
Alere i Influenza A & B assay | A: 55.2–100% B: 45.2–100% |
A: 62.5–100% B: 53.6–100% |
Nasal swabs And nasopharyngeal swab |
Influenza A & B | [293] |